Matica Bio and Cirsium Biosciences Forge Open-Access Partnership to Transform AAV Gene Therapy Manufacturing
核心洞察
Matica Biotechnology (搜索) and Cirsium Biosciences (搜索) announced Cirsium has joined the Matica Open Access Platform to enhance flexibility and scalability in AAV manufacturing.
The collaboration integrates Cirsium's novel plant-based AAV production technology with Matica Bio's downstream and analytical expertise.
The open-access model contrasts with traditional CDMO approaches by offering non-exclusive pathways, transparent data access, and freedom from long-term lock-in.
Matica Biotechnology (搜索), Inc. and Cirsium Biosciences (搜索) announced on June 16, 2026 that Cirsium has joined the Matica Open Access Platform, a move designed to accelerate flexible AAV development and manufacturing through an open, modular framework. The collaboration, which builds on the companies' existing relationship, integrates Cirsium's plant-based AAV technology with Matica Bio's downstream and analytical capabilities to improve efficiency and scalability in gene therapy production.
The partnership represents a deliberate departure from traditional contract development and manufacturing organization (CDMO) engagement models, which the companies describe as often imposing rigid workflows, limited technology transfer, and long-term lock-in. Instead, the Matica Open Access Platform provides what the partners call an "open by design" approach that gives innovators greater control over their development programs.
An Open-Access Alternative to Traditional CDMO Models
Under the new arrangement, Cirsium gains access to flexible, non-exclusive manufacturing pathways aligned with its hybrid hub-and-spoke model, transparent process development and data access for seamless knowledge transfer, interoperable technologies and partners, and accelerated scalability from early development through to commercial readiness.
"Cirsium's vision has always centered on flexibility and speed in AAV manufacturing," said Paul Kim, Chief Executive Officer of Matica Bio. "With the Matica Open Access Platform, we are extending that philosophy further, giving companies the freedom to design their own development journey without being constrained by traditional, closed CDMO models. This is about enabling innovation, not controlling it."
Kim further emphasized the platform's distinct positioning: "Many platforms in this industry are built to retain customers rather than empower them. Matica Open Access Platform is fundamentally different; it is open by design, allowing clients to move, scale, and adapt as their programs evolve."
Plant-Based Innovation Meets Downstream Expertise
Cirsium Biosciences (搜索), based in San Diego, California, operates at the intersection of biotechnology and high-tech agriculture, leveraging novel plant science to reimagine AAV production. The company's decentralized manufacturing strategy combines internal upstream plant-based production with external downstream partners, a model directly supported by the Matica Open Access Platform.
"Joining the Matica Open Access Platform is a natural extension of our mission and manufacturing model," said Dr. Daniel Gibbs, Chief Executive Officer of Cirsium Biosciences (搜索). "We founded Cirsium on the belief that the future of gene therapy depends on making production more scalable and accessible. Our platform was designed with that goal in mind, and partnerships like this are central to our progress from vision to reality."
Addressing Gene Therapy Manufacturing Barriers
The cost and complexity of AAV manufacturing remain key barriers to broader gene therapy access, and industry demand continues to grow for solutions that reduce timelines and increase scalability. By combining Cirsium's rapid, plant-based production technology with Matica's open access infrastructure, the companies aim to transform how gene therapies are developed and manufactured.
Matica Biotechnology (搜索) operates as a viral vector CDMO with a purpose-built cGMP facility and industry expertise in process development, assay development, and cGMP manufacturing. The company collaborates across five Matica sites worldwide and employs proprietary technologies including MatiMax cell lines, in-line process monitoring, and single-use technologies. Cirsium Biosciences (搜索) focuses on addressing fundamental constraints in viral vector production, including scalability, consistency, and cost, partnering with developers across the gene therapy ecosystem.